Net sales rose 42% year-over-year, but the group posted a loss due to higher costs and project delays. A 6.2 MSEK rights issue was completed, and new PFAS reduction technology was validated, positioning ECOMB for growth in bio-CCS and environmental solutions.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.